 |
|
|
| |
Potent Viral Suppression With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977 (Nucleotide NS5B Inhibitor), +/- Ribavirin, in Treatment-Naive Patients With Chronic HCV GT1, 2, or 3 (100% SVR gt1, 91% gt2)
|
| |
| |
Reported by Jules Levin
EASL 2012 Barcelona, Spain April 18-22
Sulkowski M,1 Gardiner D,2 Lawitz E,3 Hinestrosa F,4 Nelson D,5 Thuluvath P,6 Rodriguez-Torres M,7 Lok A,8 Schwartz H,9 Reddy KR,10 Eley T,2 Wind-Rotolo M,11 Huang S-P,11 Gao M,12 McPhee F,12 Hindes R,13 Symonds W,13 Pasquinelli C,2 Grasela D,2 for the AI444040 Study Group 1Johns Hopkins University, Lutherville, MD, USA; 2Bristol-Myers Squibb, Hopewell, NJ, USA; 3Alamo Medical Research, San Antonio, TX, USA; 4Orlando Immunology Center, Orlando, FL, USA; 5University of Florida, Gainesville, FL, USA; 6Mercy Medical Center, Baltimore, MD, USA; 7Fundacion de Investigacion, San Juan, Puerto Rico; 8University of Michigan, Ann Arbor, MI, USA; 9Miami Research Associates, South Miami, FL, USA; 10University of Pennsylvania, Philadelphia, PA, USA; 11Bristol-Myers Squibb, Princeton, NJ, USA; 12Bristol-Myers Squibb, Wallingford, CT, USA; 13Gilead Sciences, Foster City, CA, USA
|
| |
|
|
|
|
|
